In an important test of one of the first drugs to target core symptoms of autism, researchers are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency (also known as 22q13 Deletion Syndrome or Phelan-McDermid Syndrome), a known cause of autism spectrum disorder (ASD).
- Mount Sinai identifies first drug to demonstrate therapeutic effect in a type of autismThu, 20 May 2010, 12:40:55 EDT
- Genetic deletion discovered as risk factor for autism and schizophreniaThu, 4 Nov 2010, 14:29:26 EDT
- Agent reduces autism-like behaviors in miceWed, 25 Apr 2012, 22:32:16 EDT
- Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current testsMon, 15 Mar 2010, 1:17:13 EDT
- New findings validate the accuracy of autism diagnosis in children with Down syndromeTue, 4 Oct 2011, 17:06:02 EDT